- Details
- Written by IVN
- Category: News
Washington, DC - The U.S. Food and Drug Administration issued a warning letter to JUUL Labs Inc. for marketing unauthorized modified risk tobacco products by engaging in labeling, advertising, and/or other activities directed to consumers, including a presentation given to youth at a school. The agency also sent a letter to the company expressing concern, and requesting more information, about several issues raised in a recent Congressional hearing regarding JUUL’s outreach and marketing practices, including those targeted at students, tribes, health insurers and employers.
- Details
- Written by AHA
- Category: News
Dallas, Texas - The number of women with high blood pressure (HBP) when they become pregnant or who have it diagnosed during the first 20 weeks of pregnancy has spiked in the United States over the last four decades, especially among black women, according to new research in the American Heart Association’s journal Hypertension.
- Details
- Written by Cathy Lewis
- Category: News
New Orleans, Louisiana - Native Hawaiians who participated in a blood-pressure-lowering program incorporating their cultural dance of hula lowered their blood pressure more than those who received standard education on diet and exercise, according to preliminary research presented at the American Heart Association’s Hypertension 2019 Scientific Sessions.
- Details
- Written by IVN
- Category: News
Washington, DC - The U.S. continues to experience cases and outbreaks of measles, largely due to unvaccinated or under-vaccinated segments of the population. Measles can be a serious disease. This year has seen the greatest number of measles cases reported in the U.S. since 1992, and since measles was declared eliminated in 2000. Of those diagnosed with measles, approximately 10% have required hospitalization. The majority of cases are among people who were not vaccinated.
- Details
- Written by IVN
- Category: News
Washington, DC - The U.S. Food and Drug Administration approved Ofev (nintedanib) capsules to slow the rate of decline in pulmonary function in adults with interstitial lung disease associated with systemic sclerosis or scleroderma, called SSc-ILD. It is the first FDA-approved treatment for this rare lung condition.
- Details
- Written by Border Scope
- Category: News
Washington, DC - Press Briefing by CBP Acting Commissioner Mark Morgan:
Subcategories
Page 489 of 1259
- You are here:
-
Home
-
News
-
Latest News
- News